PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene

NCT ID: NCT00795808

Last Updated: 2008-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

171 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-08-31

Study Completion Date

2008-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Metformin increases the pregnancy rate when added to the standard treatment of anovulatory polycystic ovary syndrome (PCOS).
2. Metformin in combination with clomiphene, is more effective than clomiphene alone or metformin alone improves fertility outcomes in women with PCOS of reasonably healthy body weight (BMI \</= 32).
3. Metformin improves fertility outcomes in women with BMI \> 32 with PCOS.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Polycystic ovary syndrome PCOS Anovulation Infertility Anovulatory polycystic ovary syndrome (PCOS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BMI > 32

Women with BMI \> 32

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

500mg tds for 6 months

Placebo

Intervention Type DRUG

One tablet tds for 6 months

BMI </= 32

Women with BMI \</= 32

Group Type EXPERIMENTAL

Metformin + Clomiphene

Intervention Type DRUG

500mg tds + Ovulatory dose for 6 months

Metformin

Intervention Type DRUG

500mg tds for 6 months

Clomiphene

Intervention Type DRUG

Ovulatory dose for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin

500mg tds for 6 months

Intervention Type DRUG

Placebo

One tablet tds for 6 months

Intervention Type DRUG

Metformin + Clomiphene

500mg tds + Ovulatory dose for 6 months

Intervention Type DRUG

Metformin

500mg tds for 6 months

Intervention Type DRUG

Clomiphene

Ovulatory dose for 6 months

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women between the age of 18 and 39 years inclusive.
* Anovulatory infertility of duration at least 12 months.
* Polycystic ovary syndrome, based on Rotterdam consensus criteria.
* Normal serum prolactin, thyroid function and 17-hydroxyprogesterone.
* Normal serum prolactin, thyroid function and 17-hydroxyprogesterone;

Exclusion Criteria

* Presence of any other significant infertility factor including male factor, known tubal disease or history of an ectopic pregnancy, known endometriosis affecting the fallopian tubes or ovaries.
* Already taking oral hypoglycaemics.
* Diabetics receiving treatment.
* Renal impairment
* Chronic hepatic disease
* Cardiac Disease
* Alcohol dependency
* Pre-disposition to lactic acidosis
* Previous ovarian drilling procedure, gonadotrophin injection therapy, IUI (intrauterine insemination) or IVF ( in vitro fertilisation).
* For those women who have had previous fertility treatment, the following would be excluded:

* Women who have had \> 5 cycles of clomiphene citrate
* Women who have had \> 5 months metformin treatment previously
* Women who have proven to be resistant to 100mg or more of clomiphene citrate.
Minimum Eligible Age

18 Years

Maximum Eligible Age

39 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Auckland Medical Research Foundation

OTHER

Sponsor Role collaborator

Mercia Barnes Trust of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists

OTHER

Sponsor Role collaborator

University of Auckland, New Zealand

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University of Auckland, Fertility Plus and Repromed Auckland

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Neil P Johnson, FRANZCOG

Role: PRINCIPAL_INVESTIGATOR

University of Auckland, fertility Plus & Repromed Auckland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Auckland

Auckland, , New Zealand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

New Zealand

References

Explore related publications, articles, or registry entries linked to this study.

Johnson NP, Stewart AW, Falkiner J, Farquhar CM, Milsom S, Singh VP, Okonkwo QL, Buckingham KL; REACT-NZ (REproduction And Collaborative Trials in New Zealand), a multi-centre fertility trials group. PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. Hum Reprod. 2010 Jul;25(7):1675-83. doi: 10.1093/humrep/deq100. Epub 2010 Apr 30.

Reference Type DERIVED
PMID: 20435692 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UAuckland

Identifier Type: -

Identifier Source: org_study_id